



Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting

November 4, 2021

SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during four poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held both in person in Atlanta, GA and virtually from Saturday, December 11 to Tuesday, December 14, 2021.

"We are excited to share data at ASH that showcase scientific advancements from our *in vivo* CAR T and *ex vivo* allogeneic CAR T cell programs," said Steve Harr, Sana's President and CEO. "These presentations and publications mark the growth of our science and our continued progress toward the clinic, as we intend to file our first IND as early as next year. We celebrate our scientists as they work toward our mission of creating and delivering engineered cells as medicines for patients."

Data on the progress of several of Sana's programs were outlined in abstracts for poster presentations, which were made available to the public online today. Information about when the full posters will be available to ASH conference participants is outlined below.

Engineered hypimmune allogeneic CAR T cells exhibit innate and adaptive immune evasion even after sensitization in humanized mice and retain potent anti-tumor activity

- Abstract 1690 (Poster Presentation)
- Session Name: 703. Cellular Immunotherapies: Basic and Translational: Poster I
 - The session opens for viewing on Saturday, December 11, 2021, at 9:00 a.m. ET. Presentations are on Saturday, December 11, 2021, from 5:30 to 7:30 p.m. ET for in-person participants in the Georgia World Congress Center, Hall B5.
 - Presenter: Sonja Schrepfer
- In addition, this abstract will be published online in the November supplemental issue of *Blood*, the journal of the American Society of Hematology.

***In vivo* delivery of a CD20 CAR using a CD8-targeted fusosome in Southern pig-tail macaques (*M. nemestrina*) results in B cell depletion**

- Abstract 2769 (Poster Presentation)
- Session Name: 703. Cellular Immunotherapies: Basic and Translational: Poster II
 - The session opens for viewing on Sunday, December 12, 2021, at 9:00 a.m. ET. Presentations are on Sunday, December 12, 2021, from 6:00 to 8:00 p.m. ET for in-person participants in the Georgia World Congress Center, Hall B5.
 - Presenter: Terry Fry
- In addition, this abstract will be published online in the November supplemental issue of *Blood*, the journal of the American Society of Hematology.

CD4-targeted fusosomes are capable of transducing resting T helper cells to generate highly potent CAR T cells

- Abstract 2942 (Poster Presentation)
- Session Name: 703. Cellular Immunotherapies: Basic and Translational: Poster II
 - The session opens for viewing on Sunday, December 12, 2021, at 9:00 a.m. ET. Presentations are on Sunday, December 12, 2021, from 6:00 to 8:00 p.m. ET for in-person participants in the Georgia World Congress Center, Hall B5.
 - Presenter: Christie Ciarlo
- In addition, this abstract will be published online in the November supplemental issue of *Blood*, the journal of the American Society of Hematology.

Specificity of CD8-targeted fusosomes in human PBMCs using single cell RNA and T cell receptor sequencing

- Abstract 3983 (Poster Presentation)

- Session Name: 801. Gene Therapies: Poster III.
 - The session opens for viewing on Monday, December 13, 2021, at 9:00 a.m. ET. Presentations are on Monday, December 13, 2021, from 6:00 to 8:00 p.m. ET for in-person participants in the Georgia World Congress Center, Hall B5.
 - Presenter: Hina Iftikhar
- In addition, this abstract will be published online in the November supplemental issue of *Blood*, the journal of the American Society of Hematology.

Abstracts are available online on the ASH meeting website as of November 4, 2021, at 9:00 a.m. ET. Learn more at <https://www.hematology.org/meetings/annual-meeting>.

About Sana Biotechnology

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are more than 320 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco. For more information about Sana Biotechnology, please visit <https://sana.com/>.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws, including those related to the Company's vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical, clinical and regulatory development plans and timing expectations; the potential uses and advantages of hypoimmune CAR T cells and fusosome technology, including CD4-specific fusosomes and CD8a-targeted fusosomes; expectations for the publication of data, including in medical or scientific journals; and expectations for and the content of the Company's presentations at the 63rd American Society of Hematology Annual Meeting and Exposition. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company's current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's SEC reports, including but not limited to its Annual Report on Form 10-K dated March 24, 2021 and Quarterly Report on Form 10-Q dated August 4, 2021. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

All product and company names herein may be trademarks of their registered owners.

Investor Relations:

Nicole Keith
investor.relations@sana.com

Media:

Morgan Warners, Finsbury Glover Hering
media@sana.com